230 related articles for article (PubMed ID: 12601175)
1. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin.
Shimodaira H; Yoshioka-Yamashita A; Kolodner RD; Wang JY
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2420-5. PubMed ID: 12601175
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q.
Marinovic-Terzic I; Yoshioka-Yamashita A; Shimodaira H; Avdievich E; Hunton IC; Kolodner RD; Edelmann W; Wang JY
Proc Natl Acad Sci U S A; 2008 Sep; 105(37):13993-8. PubMed ID: 18768816
[TBL] [Abstract][Full Text] [Related]
3. ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage.
Luo Y; Lin FT; Lin WC
Mol Cell Biol; 2004 Jul; 24(14):6430-44. PubMed ID: 15226443
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage.
Gong JG; Costanzo A; Yang HQ; Melino G; Kaelin WG; Levrero M; Wang JY
Nature; 1999 Jun; 399(6738):806-9. PubMed ID: 10391249
[TBL] [Abstract][Full Text] [Related]
5. c-Jun regulates the stability and activity of the p53 homologue, p73.
Toh WH; Siddique MM; Boominathan L; Lin KW; Sabapathy K
J Biol Chem; 2004 Oct; 279(43):44713-22. PubMed ID: 15302867
[TBL] [Abstract][Full Text] [Related]
6. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
7. Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells.
Fukuhara S; Chang I; Mitsui Y; Chiyomaru T; Yamamura S; Majid S; Saini S; Deng G; Gill A; Wong DK; Shiina H; Nonomura N; Lau YF; Dahiya R; Tanaka Y
Oncotarget; 2015 Jun; 6(18):16341-51. PubMed ID: 26036629
[TBL] [Abstract][Full Text] [Related]
8. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
9. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair.
Mohd AB; Palama B; Nelson SE; Tomer G; Nguyen M; Huo X; Buermeyer AB
DNA Repair (Amst); 2006 Mar; 5(3):347-61. PubMed ID: 16338176
[TBL] [Abstract][Full Text] [Related]
10. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination.
Hosoda M; Ozaki T; Miyazaki K; Hayashi S; Furuya K; Watanabe K; Nakagawa T; Hanamoto T; Todo S; Nakagawara A
Oncogene; 2005 Nov; 24(48):7156-69. PubMed ID: 16170377
[TBL] [Abstract][Full Text] [Related]
11. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Vikhanskaya F; D'Incalci M; Broggini M
Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
[TBL] [Abstract][Full Text] [Related]
12. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog.
Aqeilan RI; Pekarsky Y; Herrero JJ; Palamarchuk A; Letofsky J; Druck T; Trapasso F; Han SY; Melino G; Huebner K; Croce CM
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4401-6. PubMed ID: 15070730
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms.
Yuan ZQ; Gottlieb B; Beitel LK; Wong N; Gordon PH; Wang Q; Puisieux A; Foulkes WD; Trifiro M
Hum Mutat; 2002 Feb; 19(2):108-13. PubMed ID: 11793469
[TBL] [Abstract][Full Text] [Related]
14. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.
Fedier A; Ruefenacht UB; Schwarz VA; Haller U; Fink D
Br J Cancer; 2002 Oct; 87(9):1027-33. PubMed ID: 12434296
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
[TBL] [Abstract][Full Text] [Related]
16. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements.
Chen J; Sadowski I
Proc Natl Acad Sci U S A; 2005 Mar; 102(13):4813-8. PubMed ID: 15781865
[TBL] [Abstract][Full Text] [Related]
17. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis.
Qin X; Zhou H; Liu L; Gerson SL
Carcinogenesis; 1999 Sep; 20(9):1667-73. PubMed ID: 10469609
[TBL] [Abstract][Full Text] [Related]
18. Deficient mismatch repair improves organismal fitness and survival of mice with dysfunctional telomeres.
Siegl-Cachedenier I; Muñoz P; Flores JM; Klatt P; Blasco MA
Genes Dev; 2007 Sep; 21(17):2234-47. PubMed ID: 17785530
[TBL] [Abstract][Full Text] [Related]
19. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.
Nakagawa T; Takahashi M; Ozaki T; Watanabe Ki K; Todo S; Mizuguchi H; Hayakawa T; Nakagawara A
Mol Cell Biol; 2002 Apr; 22(8):2575-85. PubMed ID: 11909952
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo.
Sansom OJ; Bishop SM; Court H; Dudley S; Liskay RM; Clarke AR
DNA Repair (Amst); 2003 Sep; 2(9):1029-39. PubMed ID: 12967659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]